Rationale and goals: The treatment of menopausal consequences with estrogens is controversial. The recent publication of randomized clinical trials and new therapeutical approaches has raised our interest in evaluating the evolution of its prescription in Spain during recent years as a reflection of the perception of clinicians on this topic. Methods: We have investigated the sales of prescription products with the indication of menopausal symptoms and osteoporosis from databases generated by International Marketing Services (IMS). We have gathered the annual data between 1990 and 2002 for women aged between 45 and 64. The number of units sold have been transformed in ETY's (estimated treatment years) and calculated the use trend for years. Results: The use of estrogens has increased steadily since 1990 (1.3%) until 2000 (7.8%) and then decreased slightly (7.4%). There has been a goegraphical distribution with a trend to decrease in use from north to south and from east to west. The utilization rates of hormone replacement therapy is lower than that in countries of a similar economical environment and annual income levels. There are no objective data to explain these differences. The therapeutical family of estrogens and similar molecules is the most prescribed during the peri and early post-menopausal period. Thereafter raloxifene and biphosphonates are predominantly prescribed. Conclusions: The prescibing patterns of hormone replacement, raloxifene and biphosphonates tend to coincide with a strategy based on quality evidences. Apparently prescription attitudes follow rational criteria and are based on clinicians objectives.
|Journal||Clinica e Investigacion en Ginecologia y Obstetricia|
|Publication status||Published - 1 Jan 2003|